

# Xuan-Mei Piao

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/884148/publications.pdf>

Version: 2024-02-01

25  
papers

317  
citations

933447

10  
h-index

940533

16  
g-index

25  
all docs

25  
docs citations

25  
times ranked

471  
citing authors

#	ARTICLE	IF	CITATIONS
1	Anti-inflammatory action of <i>Athyrium multidentatum</i> extract suppresses the LPS-induced TLR4 signaling pathway. <i>Journal of Ethnopharmacology</i> , 2018, 217, 220-227.	4.1	37
2	Role of Exosomal miRNA in Bladder Cancer: A Promising Liquid Biopsy Biomarker. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1713.	4.1	36
3	Urinary cell-free microRNA biomarker could discriminate bladder cancer from benign hematuria. <i>International Journal of Cancer</i> , 2019, 144, 380-388.	5.1	30
4	Unmasking molecular profiles of bladder cancer. <i>Investigative and Clinical Urology</i> , 2018, 59, 72.	2.0	23
5	Collagen type $\alpha 1$ and 2 repress the proliferation, migration and invasion of bladder cancer cells. <i>International Journal of Oncology</i> , 2021, 59, .	3.3	21
6	Identification of differentially expressed miRNAs and miRNA-targeted genes in bladder cancer. <i>Oncotarget</i> , 2018, 9, 27656-27666.	1.8	20
7	Methylation Signature for Prediction of Progression Free Survival in Surgically Treated Clear Cell Renal Cell Carcinoma. <i>Journal of Korean Medical Science</i> , 2019, 34, e144.	2.5	17
8	Kinesin Family Member 11 mRNA Expression Predicts Prostate Cancer Aggressiveness. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 450-454.	1.9	14
9	Urinary microRNA-1913 to microRNA-3659 expression ratio as a non-invasive diagnostic biomarker for prostate cancer. <i>Investigative and Clinical Urology</i> , 2021, 62, 340.	2.0	14
10	Urinary Cell-Free DNA IQGAP3/BMP4 Ratio as a Prognostic Marker for Non-Muscle-Invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e704-e711.	1.9	12
11	A prognostic immune predictor, HLA-DRA, plays diverse roles in non-muscle invasive and muscle invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 237.e21-237.e29.	1.6	12
12	Diagnostic value of combined IQGAP3/BMP4 and IQGAP3/FAM107A expression ratios in urinary cell-free DNA for discriminating bladder cancer from hematuria. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 86-96.	1.6	11
13	A novel tumor suppressing gene, ARHGAP9, is an independent prognostic biomarker for bladder cancer. <i>Oncology Letters</i> , 2020, 19, 476-486.	1.8	9
14	Molecular Progression Risk Score for Prediction of Muscle Invasion in Primary T1 High-Grade Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 274-280.	1.9	8
15	Adventitious root cultures of <i>Oplopanax elatus</i> inhibit LPS-induced inflammation via suppressing MAPK and NF- $\kappa$ B signaling pathways. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 2019, 55, 766-775.	1.5	8
16	Prognostic Value of BUB1 for Predicting Non-Muscle-Invasive Bladder Cancer Progression. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12756.	4.1	7
17	ZNF492 and GPR149 methylation patterns as prognostic markers for clear cell renal cell carcinoma: Array-based DNA methylation profiling. <i>Oncology Reports</i> , 2019, 42, 453-460.	2.6	6
18	A Molecular Signature Determines the Prognostic and Therapeutic Subtype of Non-Muscle-Invasive Bladder Cancer Responsive to Intravesical Bacillus Calmette-Guérin Therapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1450.	4.1	6

#	ARTICLE	IF	CITATIONS
19	Cardamine komarovii flower extract reduces lipopolysaccharide-induced acute lung injury by inhibiting MyD88/TRIF signaling pathways. Chinese Journal of Natural Medicines, 2019, 17, 461-468.	1.3	5
20	Integrative Transcriptome Profiling Reveals SKA3 as a Novel Prognostic Marker in Non-Muscle Invasive Bladder Cancer. Cancers, 2021, 13, 4673.	3.7	5
21	Expression of hsv1-miR-H18 and hsv2-miR-H9 as a field defect marker for detecting prostate cancer. Prostate International, 2022, 10, 1-6.	2.3	5
22	Prominence of urinary biomarkers for bladder cancer in the COVID-19 era: From the commercially available to new prospective candidates. Investigative and Clinical Urology, 2021, 62, 500.	2.0	4
23	Urinary hsv2-miR-H9 to hsa-miR-3659 ratio is an effective marker for discriminating prostate cancer from benign prostate hyperplasia in patients within the prostate-specific antigen grey zone. Investigative and Clinical Urology, 2022, 63, 238.	2.0	3
24	Expression of phosphorylated p21-activated kinase 4 is associated with aggressive histologic characteristics and poor prognosis in patients with surgically treated renal cell carcinoma. Investigative and Clinical Urology, 2021, 62, 399.	2.0	2
25	Expression of RPL9 predicts the recurrence of non-muscle invasive bladder cancer with BCG therapy. Urologic Oncology: Seminars and Original Investigations, 2022, , .	1.6	2